BOSTON (AP) — BOSTON (AP) — Verve Therapeutics Inc. (VERV) on Tuesday reported a loss of $50.1 million in its third quarter.

On a per-share basis, the Boston-based company said it had a loss of 59 cents.

The results topped Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 70 cents per share.

The biotechnology firm posted revenue of $6.9 million in the period.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on VERV at https://www.zacks.com/ap/VERV